We sought to evaluate the response to PD-1/PDL-1 CPI in patients with MSI-H and/or high TMB solid malignancies.Methods:Retrospective analysis of 16 patients (pts) who received 18 CPI-based therapies between October 2017 and February 2022. MSI-H and TMB status was assessed by CARIS, ...
1441#Background:Data suggest that patients with tumors with microsatellite instability (MSI-H), EBV expression, or positive PD-L1 expression can benefit from immunotherapy. This trial evaluated PD-1 immunotherapy in this subset of patients with operable gastric cancer.Methods:We present results of ...
Though several anti-PD-1/PD-L1 antibodies approved for monotherapy in microsatellite instability-high or mismatch repair-deficient unresectable/metastatic solid tumors, novel immunotherapy with better anti-tumor activity is needed in clinic. In this single-arm, multicenter, pivotal, phase II study, ...